Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche seeks US approval for kidney drug
If approved, analysts predict that the drug could achieve sales of up to $2 billion per year. However, Cera is currently the subject of a lawsuit being brought
If approved, analysts predict that the drug could achieve sales of up to $2 billion per year. However, Cera is currently the subject of a lawsuit being brought
The primary aim of the clinical trial is to assess the safety and efficacy of a single dose of AZ-002 in treating a pharmacologically-induced panic attack. Changes in
The Rasilez application includes data from more than 6,000 people with high blood pressure. In these studies Rasilez produced significant blood pressure reductions sustained over 24 hours. Sustained
Two decades after the first drugs produced by biotechnological means arrived on the EU market, a number of these patents are expiring. This means that the first 'biogenerics'
Fast Track designation allows FDA to expedite review of drugs and biologics for serious or life-threatening conditions which demonstrate the potential to address unmet medical needs. An important
As all regulatory approvals for the takeover have already been received, Chiron said that it expects the transaction to be completed before the end of Thursday 20th April.
Pathogenics retains the exclusive worldwide rights to NCT for all indications other than ophthalmic (eye related) applications. Acuity is paying Pathogenics an up-front licensing fee and minimum annual
Preliminary results from this trial indicate that treatment with PRX-08066 resulted in a statistically significant reduction in systolic pulmonary blood pressure during exercise hypoxia. The trial explored the
The FDA letter states that approval is subject only to final review by the FDA of the package inserts for each of the products, a review which has
Results of the study demonstrated that ACP-103 induced a robust and statistically significant increase in slow wave sleep that was dose-related. ACP-103 treatment also had a positive impact